Can histone deacetylase inhibitors uncover novel therapeutic agents for inherited retinal dystrophies
|Title:||Can histone deacetylase inhibitors uncover novel therapeutic agents for inherited retinal dystrophies||Authors:||Sundaramurthi, Husvinee
|Permanent link:||http://hdl.handle.net/10197/10357||Date:||13-Dec-2017||Online since:||2019-05-08T14:06:55Z||Abstract:||Inherited retinal dystrophies (iRDs) affect 1 in 3000 people worldwide and effective treatment options are not widely available due to the genetic and clinical heterogeneity. Recently, histone deacetylase inhibitors (HDACi) have gained attention as a potential therapeutic option based on their neuroprotective effects within the retina. However, the benefits of HDACi remains highly controversial, and their downstream mechanism of action are yet to be thoroughly elucidated. Preliminary data from studies conducted has shown that treatment of zebrafish retinal mutant with HDACi, trichostatin A (TSA), could rescue visual capacity and retinal morphology. The current study is designed to address the suitability of HDACi as therapeutic options for iRDs using zebrafish models.||Type of material:||Conference Publication||Keywords:||Inherited retinal dystrophies (iRDs); Treatment options; Histone deacetylase inhibitors (HDACi); Neuroprotective effects; Retina; Visual capacity; Retinal morphology||Other versions:||https://www.emedevents.com/c/medical-conferences-2017/british-pharmacological-society-bps-pharmacology-2017||Language:||en||Status of Item:||Peer reviewed||Conference Details:||British Pharmacological Society (BPS) Pharmacology 2017, London, England, 11-13 December 2017|
|Appears in Collections:||Biomolecular and Biomedical Science Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.